medscape.com
Cure8 news brief
Why This Matters
Meeting highlights summarize several studies that could affect treatment choices for Crohn’s disease and IBD — including positive data for risankizumab and investigational oral IL‑23 therapy, plus signals that guselkumab might affect fibrostenotic disease.
These findings may expand future treatment options and inform research on who responds to biologics.
Who Should Pay Attention
Adults with Crohn's disease or IBD (especially patients on biologics or with stricturing disease), gastroenterologists/IBD clinicians, and researchers studying IL‑23 therapies or biomarkers of response.
Study Snapshot
Story typeResearch news
Evidence typeClinical study
Source depthFull source text
What To Know
The article summarizes multiple presentations rather than reporting a single trial in full detail. It notes a risankizumab induction and maintenance study showing higher clinical response and some endoscopic benefit versus placebo through 24 weeks.
A post hoc analysis suggested guselkumab may improve intestinal stenosis versus ustekinumab over longer follow-up and found differences in fibroblast-related gene modules. An oral peptide, icotrokinra, was reported to sustain responses through week 76 in an extension, with no new safety signals reported.
The piece also mentions research on antidrug antibodies and infliximab response. The write-up is a meeting highlights commentary and does not present full protocols, full datasets, or regulatory conclusions.
If you’re following a specific medication or considering clinical trials, discuss details with your gastroenterology team to interpret how these early/meeting results might relate to individual care.
Keep In Mind
This is a Medscape commentary summarizing presentations from ACG 2026. Meeting abstracts and presentations often precede full peer‑reviewed publications; details such as full trial protocols, endpoints, and complete safety data may be published later. Discuss applicability to individual care with your clinician.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical study
Article type assigned from Cure8 classification; confirm details in the original source.
Publicationmedscape.com
PublisherMedscape
AuthorsDavid A. Johnson, MD
Indexed viaGoogle News
Source typeWeb article
PublishedOct 27, 2026, 12:40 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
6 GI Studies That Could Shift IBD Care and CRC Screening - Medscape
New and longer-term data presented at ACG 2026 may expand treatment options for Crohn’s disease, including an oral IL-23–targeted peptide and potential effects of guselkumab on intestinal strictures, which could affect...
Differential long-term efficacy of biologic and small-molecule therapies by disease location in moderate-to-severe luminal Crohn's disease: a systematic review and network meta-analysis.
The analysis suggests that some biologic and small-molecule therapies work differently depending on whether Crohn's disease affects the ileum, colon, or both — information that could help tailor long-term treatment...
Medical Therapies Beyond Infliximab for Perianal Fistulizing Crohn's Disease: Current Evidence and Future Perspectives.
Perianal fistulas are a common, hard-to-heal complication of Crohn's disease. This review collects current options beyond infliximab and explains where evidence is stronger or still emerging, which can help patients and...